PREDICT underestimates survival of patients with HER2-positive early-stage breast cancer

The prognostic performance of PREDICT in patients with HER2-positive early breast cancer (EBC) treated in the modern era with effective chemotherapy and anti-HER2 targeted therapies is unclear. Therefore, we investigated its prognostic performance using data extracted from ALTTO, a phase III trial e...

Descripción completa

Detalles Bibliográficos
Autores principales: Agostinetto, Elisa, Ameye, Lieveke, Martel, Samuel, Aftimos, Philippe, Pondé, Noam, Maurer, Christian, El-Abed, Sarra, Wang, Yingbo, Vicente, Malou, Chumsri, Saranya, Bliss, Judith, Kroep, Judith, Colleoni, Marco, Petrelli, Fausto, Del Mastro, Lucia, Moreno-Aspitia, Alvaro, Piccart, Martine, Paesmans, Marianne, de Azambuja, Evandro, Lambertini, Matteo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9300724/
https://www.ncbi.nlm.nih.gov/pubmed/35859079
http://dx.doi.org/10.1038/s41523-022-00452-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9300724/
https://www.ncbi.nlm.nih.gov/pubmed/35859079
http://dx.doi.org/10.1038/s41523-022-00452-8

Ejemplares similares